| Update on emerging therapies for multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 20662750 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and treatment of Alzheimer's disease and dementia, cerebrovascular and neuromuscular disorders, as well as the rapidly changing areas of genetic testing and stem cell research. This meeting report focuses on the latest therapies in the treatment of multiple sclerosis (MS). |
| | |
Authors:
|
Eppie M Yiu; Brenda Banwell |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 10 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-28 Completed Date: 2010-12-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 1259-62 Citation Subset: IM |
Affiliation:
|
The Hospital for Sick Children, Toronto, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cladribine
/
therapeutic use* Humans Immunosuppressive Agents / therapeutic use* Mesenchymal Stem Cell Transplantation / methods Mesenchymal Stem Cells* Multiple Sclerosis / physiopathology, therapy* Neurology / methods* Propylene Glycols / therapeutic use* Sphingosine / analogs & derivatives*, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 0/Propylene Glycols; 123-78-4/Sphingosine; 162359-55-9/fingolimod; 4291-63-8/Cladribine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New perspectives on molecular and cellular mechanisms of neuroprotection and neuroregeneration: part...
Next Document: Physical activity and the risk of stroke.